1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Penetrium Bioscience Inc.

Penetrium Bioscience Inc.

KKRX:187660
5,770.00
KRW
+140.00
(+2.49%)
-289.93EPS
296.89BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
43,883.72
302.81
359.58
329.7
316.55
307.96
217.62
189.04
153.01
Basic EPS, GAAP
8,896.88
22.67
103.45
45.35
5.67
-66.33
-448.78
-302.32
-300.06
Free Cash Flow per Basic Share
10,672.8
35.65
143.6
-9.74
-14.21
-82.68
-321.33
-106.99
-78.48
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
82.33
235.58
310.24
726.59
677.56
606.32
152.35
371.24
395.55
Tangible Book Value per Share
80.36
233.85
308.65
724.8
655.82
582.17
147.09
368.07
393
Basic Weighted Avg Shares
- -
34
36
42
47
45
45
49
55
Sales/Revenue/Turnover
2,389
10,206
13,120
13,978
14,883
13,790
9,745
9,273
8,344
Operating Margin (%)
4.18
8.34
26.91
14.96
-5.07
-13.86
-163.49
-79.55
-80.3
Depreciation Expense
16
499
534
702
1,086
1,559
1,589
1,113
1,000
Net Income, GAAP
484
764
3,775
1,923
267
-2,970
-20,096
-14,830
-16,364
Effective Tax Rate (%)
16.74
25.15
22.42
20.42
176.91
- -
- -
- -
- -
Profit Margin (%)
20.27
7.49
28.77
13.75
1.79
-21.54
-206.22
-159.92
-196.11
Working Capital
4,184
10,066
12,986
30,959
26,382
10,259
-9,226
-1,146
-4,784
LT Debt
- -
- -
20
10
251
267
449
31
202
Total Equity
3,912
10,958
14,413
33,457
30,710
27,128
6,629
21,527
22,936
Return on Invested Capital (%)
- -
8.14
20.35
6.74
1.78
- -
- -
- -
- -
Return on Capital (%)
- -
11.76
30.75
8.9
0.62
- -
- -
- -
- -
Return on Common Equity (%)
- -
10.4
29.92
8.02
0.83
-10.33
-118.31
-104.62
-104.28

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,430
5,327
5,243
LT Borrowings
- -
- -
- -
LT Finance Leases
31
20
202
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
130,384
605,352
296,889

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,347
5,969
4,511
Cash, Cash Equivalents & STI
4,846
2,314
501
Accounts Receivable, Net
1,104
619
528
Inventories
- -
- -
- -
Total Current Liabilities
10,493
9,927
9,295
Payables & Accruals
- -
- -
- -
ST Debt
5,430
5,327
5,243
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
52.29%
224.76%
Free Cash Flow
- -
126.61%
-63.53%
Net Income, GAAP
- -
-159.88%
-26.21%
Sales/Revenue/Turnover
- -
-5.7%
-4.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,933
2,627
2,045
2,141
9,745
2025
2,213
2,524
2,607
1,930
9,273
2026
1,692
2,116
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-31.18
-278.69
-79.62
-59.28
-448.78
2025
-81.25
40.62
-166.12
-83.14
-302.32
2026
-32.19
-27.57
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
110
Sector
Health services
Industry
Medical/Nursing services
Address
Seoul South Korea
IPO Date
Jun 3, 2021
Website
penetriumbio.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Penetrium Bioscience Inc. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the discovery, research, and development of novel biotherapeutics and multi-target fusion proteins for the treatment of metabolic disorders, immuno-oncology, and autoimmune diseases. The company develops therapeutic assets utilizing its proprietary platform technologies, primarily the NTIG (Non-covalent Triple Immunoglobulin) platform, which facilitates the design of long-acting, multi-specific fusion proteins with customizable pharmacokinetics and enhanced tissue penetration capabilities. The company operates through integrated biopharmaceutical research and drug development segments, offering an investigational pipeline that includes: PG-102, a long-acting dual GLP-1 and GLP-2 receptor agonist developed for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH); PG-101, an engineered interleukin-2 (IL-2) fusion protein targeting advanced solid tumors and refractory cancers; PG-105, a multi-specific fusion protein candidate for immuno-oncology applications; and PG-110, an investigational biologic candidate directed at chronic inflammatory and autoimmune conditions. In addition to internal pipeline advancement, the company provides collaborative research, preclinical candidate optimization, protein engineering, and technology out-licensing services to international biotechnology and pharmaceutical partners. In recent corporate developments, Yuhan Corporation completed a strategic equity investment to become the company's largest shareholder, establishing a joint development partnership focused on co-advancing the PG-102 metabolic pipeline and next-generation dual-target biologics. The company has also progressed PG-102 through Phase 1 clinical trial evaluations to assess safety, pharmacokinetics, and glycemic modulation, while continuing to expand its international patent portfolio covering multi-target fusion constructs and drug delivery mechanisms across North America, Europe, and Asia. Founded in 1998, Penetrium Bioscience Inc. is headquartered in Seoul, South Korea.